04:00 PM EDT, 05/02/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We lower our 12-month target by $10 to $45, 10.7x our FY 25 (Sep.) EPS estimate, a discount to HOLX's historical forward average due to softness in the Breast Health segment. We cut both our FY 25 and FY 26 EPS estimate by $0.05 to $4.20 and 4.56, respectively. Mar-Q EPS of $1.03 vs. $1.03, was a cent above the S&P Capital IQ consensus estimate. HOLX's performance was marked by contrasting trends across its business. Diagnostics, the largest segment, demonstrated resilience with a 0.8% Y/Y revenue increase, driven by growth in molecular diagnostics. However, the Breast Health segment faced significant headwinds, with revenue declining 7.4% due to weakness in mammography capital equipment sales. HOLX maintained its FY 25 revenue guidance but lowered its EPS outlook by $0.10 to a $4.20 midpoint, due to concerns over tariffs and geopolitical conditions. We expect continued soft demand in Breast Health, though think recent acquisitions of Endomagnetics and Gynesonics can help contribute to future growth.